Description

OVA G4 peptide TFA is a variant of the agonist ovalbumin (OVA) peptide SIINFEKL (257-264). SIINFEKL is routinely used to stimulate ovalbumin-specific T cells and to test new vaccine adjuvants can form a stable hydrogel[1][2].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)–Neuroscience-Neuromodulation–C45H72F3N9O14—-[1]François P, et al. Phenotypic model for early T-cell activation displaying sensitivity, specificity, and antagonism. Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):E888-97.|[2]Kamalov M,et al. Ovalbumin Epitope SIINFEKL Self-Assembles into a Supramolecular Hydrogel. Sci Rep. 2019 Feb 25;9(1):2696.—-1020.10–99.70–CC(C)C[C@@H](C(O)=O)NC([C@H](CCCCN)NC([C@H](CCC(O)=O)NC([C@H](CC1=CC=CC=C1)NC(CNC([C@H]([C@@H](C)CC)NC([C@H]([C@@H](C)CC)NC([C@H](CO)N)=O)=O)=O)=O)=O)=O)=O.OC(C(F)(F)F)=O–Inflammation/Immunology–H2O : 6.67 mg/mL (ultrasonic)–Others—-Others–Peptides